MSN Labs launches antiviral drug Faripiravir to treat COVID-19

The drug has reportedly attained approved by the DCGI (Drug Controller General of India)

India has witnessed a record increase in the number of COVID-19 cases over the past month which has caused a significance shortage of needed drugs to treat symptoms incurred by the deadly virus. In view of mounting requirement for required medications, Indian pharmaceutical firm, MSN Laboratories Pvt. Ltd. has launched a generic version of its antiviral drug Faripiravir to treat moderate and mild Covid-19.

Sold under the name Favilow 800 mg, the drug will be available across various pharmacies. To speed up its reach to patients, MSN Labs’ team will be helping out with free home delivery in more than 170 cities in tandem with local retail chemists.

MSN Reddy, MD and Chairman, MSN Group, conveyed that with rising cases of Covid-19 in India, the need for affordable treatment options has heightened. Their firm is confident that its product, Favilow 800, would offer support to the nation’s efforts in tackling the COVID crisis.

In August 2020, MSN had launched Favilow in low strengths of 200mg and 400 mg. However, with the launch of its latest 800mg variant, MSN claims that the high strength drug will improve patient compliance and experience by effectively reducing the number of tablets needed to be consumed by a patient per day. The launch would also address the shortages and issues faced by patients in procuring the Covid-19 drug.

Bharat Reddy, Executive Director, MSN Group, mentioned that the company has formulated more than 100,000 dosage regimen for the treatment of Covid-19 in last 15 days, and is scaling up production volumes to 600,000 to 800,000 dosage regimen by next month.

While an official report confirmed that the higher strength Favipiravir 800 mg drug has reportedly attained approved by the DCGI (Drug Controller General of India).

Source Credit: